Ludwig Cancer Research scientists have devised new types of chimeric antigen-receptor (CAR) T cells—a type of cancer immunotherapy—that can be switched on to varying degrees of intensity and then switched off on demand with existing drugs. The design and preclinical evaluation of the CAR-T cells, led by Melita Irving and Greta Maria Paola Giordano Attianese of the Lausanne Branch of the Ludwig Institute for Cancer Research, is detailed in Proceedings of the National Academy of Sciences.
Medical Xpress – latest medical and health news stories
